1. Home
  2. CMPS vs FTRE Comparison

CMPS vs FTRE Comparison

Compare CMPS & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COMPASS Pathways Plc American Depository Shares

CMPS

COMPASS Pathways Plc American Depository Shares

HOLD

Current Price

$12.11

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$16.56

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPS
FTRE
Founded
2020
1996
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
CMPS
FTRE
Price
$12.11
$16.56
Analyst Decision
Strong Buy
Buy
Analyst Count
8
9
Target Price
$25.38
$14.06
AVG Volume (30 Days)
4.0M
1.1M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.00
52 Week Low
$2.25
$4.46
52 Week High
$14.76
$18.67

Technical Indicators

Market Signals
Indicator
CMPS
FTRE
Relative Strength Index (RSI) 56.69 63.11
Support Level $5.48 $15.66
Resistance Level $14.76 $18.08
Average True Range (ATR) 0.99 1.09
MACD -0.25 0.05
Stochastic Oscillator 35.33 78.80

Price Performance

Historical Comparison
CMPS
FTRE

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Share on Social Networks: